Nerve function in advanced bladder cancer patients on EV therapy
Part of Cancer clinical trials.
This study looks at whether enfortumab vedotin (EV) affects the nervous system in people with advanced bladder cancer. It follows patients who are getting EV (alone or with immunotherapy) to see how their nerve function changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older.
- You have a type of bladder cancer called urothelial carcinoma.
- Your cancer has spread to nearby tissues or to other parts of the body.
- You are scheduled to receive treatment with enfortumab vedotin (EV), either alone or with other drugs.
- You agree to have regular check-ups to monitor your nervous system function.
- You agree to let the study team access your medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how enfortumab vedotin, a cancer drug, affects the nerves. It aims to understand and track neuropathy (nerve damage) in people with urothelial carcinoma, so doctors can better manage side effects.
This study watches for nerve damage (peripheral neuropathy) in patients receiving two cancer drugs—enfortumab vedotin and pembrolizumab—for advanced bladder cancer. Researchers will test whether a supportive medication called Neuridase can help prevent or reduce nerve pain and numbness that sometimes occurs with this treatment.
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
This study looks at how well the combination of enfortumab vedotin and pembrolizumab (EV+P) works as the first treatment for people with advanced or metastatic bladder cancer or other rare urinary tract tumors. By reviewing medical records, researchers hope to learn more about the benefits of this therapy.
This trial tests a drug called EV for people with recurrent endometrial cancer that has gotten worse after treatment. It may help if your cancer cells have a specific protein called nectin-4.
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
Hear when a new Locally Advanced or Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.